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A B S T R A C T
Low back pain is a complex, multifactorial, and heterogeneous condition, but this does not make it an exception in medicine. Management of low back pain based on
a mechanistic approach and developing more effective multidisciplinary treatment is possible and would finally implement the biopsychosocial model of care.
1. Introduction
Low back pain (LBP) remains the leading cause of disability
worldwide (GBD, 2016 Disease and Injury Incidence and Prevalence
Collaborators., 2017), and the most expensive health problem in many
countries (Dagenais et al., 2008). While attempts to address this
growing problem centred on reform of the current management of LBP,
parallel evidence from basic sciences and advanced imaging indicates
that management of LBP may significantly benefit from a mechanistic
approach toward pain classification and treatment in the foreseeable
future. We define a mechanism-based approach to LBP as one that goes
beyond anatomical and pathological factors, attempting to identify
mechanisms at different levels of peripheral and central nervous system
and provide individualized treatments targeting relevant inflammatory
factors and molecules, especially when directed toward patients with
distinct pain states and mechanisms; i.e., nociceptive, neuropathic,
peripheral sensitization, and central sensitization (Vardeh et al., 2016).
Here, we highlight several signs that we believe point to such changes
in hopes to begin a discussion among clinicians and researchers to give
rise to a new, improved approach toward care.
2. The problem
The current approach to LBP management classifies more than 85%
of patients as having non-specific low back pain (NSLBP), defined as
LBP without a specific physical cause, and diagnostic procedures to
reduce this percentage are discouraged by current clinical guidelines.
Over the last three decades, several factors have led clinicians and
clinical researchers to embrace the term NSLBP for use in practice and
research without the need to identify the exact origin of pain. First, the
prior pathoanatomic approach was too simplistic as it proved im-
possible to find the origins of pain in the majority of patients.
Importantly, degenerative and pathological findings, suspected causes
of LBP, were frequently reported in asymptomatic subjects.
Consequently, the bio- aspect was lost from the biopsychosocial model,
largely because of unfulfilled promises of the biological approach.
Second, an optimistic view about potential spontaneous recovery of LBP
expedited the trend of refraining from diagnostics and treatment in
acute pain and led to the idea that treatment and hence diagnostics
were not needed. Finally, a shift in focus from acute to chronic LBP,
which accounts for the bulk of the costs associated with LBP,
strengthened this paradigm shift to NSLBP.
3. The transition
While managing NSLBP and its related disabilities as a multi-
dimensional problem was successful in some ways, recommended
treatments for NSLBP show small effect sizes, adherence to evidence-
based clinical guidelines is low, and use of imaging, medication, and
physicians' referrals are increasing (Mafi et al., 2013). To address this
problem, subgrouping of NSLBP patients (based on neuromuscular,
psychological or prognostic factors or treatment-based classifications)
and directing specific treatments to the targeted subgroups has been
proposed and may have marginally improved treatment effect sizes.
However, evidence for the effectiveness of this approach is still incon-
sistent.
Several key factors are now in favor of the management of LBP
based on mechanistic diagnosis and targeted treatment. First, recent
evidence indicates that we may now be closer than ever to identifying
underlying mechanisms in many more cases of LBP (Table 1). Second,
there is a preference among patients to understand the diagnosis of
their problem over simply managing their pain and maintaining func-
tion. In fact, acute LBP is in many cases not as self-limiting as previously
thought (Wirth et al., 2017), so that a lack of specific diagnosis might
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have negative psychological consequences that would contribute to
pain becoming chronic. Third, and more optimistically, mechanism-
based classification and treatment of LBP may receive more research
and clinical attention by the advent of novel treatments such as re-
generative therapies that require early detection of degenerative
changes (Sakai and Andersson, 2015), and the rise of personalized and
precision medicine that aims to use biomarkers to select patients for
targeted, personalized treatment (Collins and Varmus, 2015).
4. The path forward
A close multidisciplinary collaboration between clinicians and re-
searchers could lay the ground for such a movement leading to more
effective treatment: 1) with appropriate targeting, exercise might as-
sume new roles in facilitating repair of early degenerative changes
(with low load, dynamic exercises) (Belavý et al., 2017) and reducing
inflammatory components of LBP, 2) pharmacologic therapies could
move from symptomatic to causal, targeting relevant inflammatory
factors and molecules, especially when directed toward patients with
distinct pain states and mechanisms (Vardeh et al., 2016), and 3) sur-
gical intervention would be more effective if it could target the struc-
tures and mechanisms underpinning LBP with greater precision. Ad-
vances in electronic health records are also important infrastructures to
integrate these efforts and support development of new diagnostic
procedures and treatments for LBP. The time is also right for such a
transition, as healthcare and treatments for various conditions begin to
consider more directly each individual patient's needs based on geno-
mics, biomarkers, function, and lifestyle (Collins and Varmus, 2015).
In conclusion, we propose that the time is appropriate to re-assess
mechanism-based diagnosis and treatment of LBP. Controversies sur-
rounding mechanistic and non-mechanistic causal explanations of
diseases and medical outcomes continue in the philosophy of medicine
(Reiss and Ankeny, 2016). However, in such a complex phenomenon as
LBP, with basic science pointing to previously unknown mechanisms, it
seems likely that doing so would change LBP management for the
better. Obviously, this claim is open for debate and discussion and
should be tested in thorough clinical studies.
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Table 1
Examples of recent evidence on biological factors that may provide targets for
treatment in LBP.
Central neurological factors.
fMRI studies have revealed clear evidence of altered and reversible changes in
pain processing in the brain of chronic LBP patients (Nijs et al., 2017).
Glial activation, which plays a key role in persistent pain, has been demonstrated
in the thalamus and somatosensory areas representing the lumbar spine of
chronic LBP patients (Loggia et al., 2015).
Peripheral neurological factors.
A link between sensory nerve ingrowth into the inner layer of intervertebral discs
(IVDs), a potential source of LBP, and degeneration of the (IVD) has been
proposed (Ohtori et al., 2015). TNF-Alpha in nucleus pulposus and interleukins
may induce this sensory nerve growth (Hayashi et al., 2008). There is also
evidence of association between painful intervertebral disc degeneration and
nerve injury (Lim et al., 2017).
Inflammatory factors.
Higher serum levels of interleukin-6 (IL-6) were found in patients with
degenerative disc disease or spinal stenosis compared to control subjects (Weber
et al., 2016). There is also evidence of elevated levels of C-reactive protein and
IL-6 in acute LBP, which were correlated with symptom severity (Klyne et al.,
2017).
Genetic and molecular factors.
Several single-nucleotide polymorphisms (SNPs) were identified as potential risk
factors for intervertebral disc degeneration (Martirosyan et al., 2016). Molecular
profiles of human annulus fibrosus and nucleus pulposus cells were identified
that can facilitate cell-based therapies for lumbar discogenic pain (Tang et al.,
2016).
Structural factors.
Significant associations were found between MRI findings such as Modic changes
and episodes of severe and disabling LBP, persistent LBP, disc pathology and
endplate abnormalities (Luoma et al., 2016; Määttä et al., 2015).
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